Construction and Analysis of lncRNA-Mediated ceRNA Network in Cervical Squamous Cell Carcinoma by Weighted Gene Co-Expression Network Analysis.
Carcinoma, Squamous Cell
/ genetics
Female
Gene Expression Regulation, Neoplastic
Gene Ontology
Gene Regulatory Networks
Genes, Neoplasm
Humans
Kaplan-Meier Estimate
MicroRNAs
/ genetics
Middle Aged
Protein Interaction Maps
/ genetics
RNA, Long Noncoding
/ genetics
RNA, Messenger
/ genetics
RNA, Neoplasm
/ genetics
Uterine Cervical Neoplasms
/ genetics
Journal
Medical science monitor : international medical journal of experimental and clinical research
ISSN: 1643-3750
Titre abrégé: Med Sci Monit
Pays: United States
ID NLM: 9609063
Informations de publication
Date de publication:
09 Apr 2019
09 Apr 2019
Historique:
entrez:
10
4
2019
pubmed:
10
4
2019
medline:
3
8
2019
Statut:
epublish
Résumé
BACKGROUND More and more recent studies have clearly shown that long non-coding RNA (lncRNA) should be considered as a fundamental part of the ceRNA network, mainly because lncRNA can act as miRNA sponges to regulate the protein-coding gene expression. Nevertheless, it is still not clear how lncRNA-mediated ceRNAs function in cervical squamous cell carcinoma (CESC). Moreover, information about the ceRNA regulatory mechanism is also remarkably limited; thus, prediction of CESC prognosis using ceRNA-related information remains challenging. MATERIAL AND METHODS We collected 306 RNA (lncRNA, miRNA, and mRNA) expression profile datasets obtained from cervical squamous cancer tissues plus 3 more from adjacent cervical tissues via the TCGA database. Subsequently, we constructed a lncRNAs-miRNAs-mRNAs CESC ceRNA network, and Gene Ontology (GO) analysis was carried out. RESULTS We identified a total of 30 DElncRNAs, 70 DEmiRNAs, and 1089 DEmRNAs in CESC. Subsequently, to reveal the expression patterns of dysregulated genes, weighted gene co-expression network analysis was carried out, resulting in 3 co-expression modules with significantly related clinical properties. The constructed aberrant lncRNAs-miRNAs-mRNAs CESC ceRNA network was composed of 17 DEmiRNAs, 5 DElncRNAs, and 7 DEmRNAs. Moreover, the survival analysis was performed for DElncRNAs, DEmiRNAs, and DEmRNAs. CONCLUSIONS The present study shows the involvement of the lncRNA-related ceRNA network in the pathogenesis of CESC. We believe the newly generated ceRNA network will provide more insights into the lncRNA-mediated ceRNA regulatory mechanisms.
Identifiants
pubmed: 30965350
pii: 913471
doi: 10.12659/MSM.913471
pmc: PMC6474298
doi:
Substances chimiques
MicroRNAs
0
RNA, Long Noncoding
0
RNA, Messenger
0
RNA, Neoplasm
0
Types de publication
Journal Article
Langues
eng
Pagination
2609-2622Références
Nature. 2001 Feb 15;409(6822):814-6
pubmed: 11236992
ORL J Otorhinolaryngol Relat Spec. 2001 Jul-Aug;63(4):229-32
pubmed: 11408819
BMC Bioinformatics. 2008 Dec 29;9:559
pubmed: 19114008
Virology. 2009 Feb 20;384(2):260-5
pubmed: 19135222
ScientificWorldJournal. 2010 Jan 08;10:90-102
pubmed: 20062956
Genome Biol. 2011;12(2):R16
pubmed: 21324177
BMC Cancer. 2011 Feb 22;11:80
pubmed: 21338529
Gynecol Oncol. 2011 Oct;123(1):157-63
pubmed: 21742370
Cell. 2011 Aug 5;146(3):353-8
pubmed: 21802130
Asian Pac J Cancer Prev. 2013;14(9):5101-5
pubmed: 24175783
Nature. 2014 Feb 20;506(7488):371-5
pubmed: 24390348
Tumour Biol. 2014 Dec;35(12):11913-20
pubmed: 25142231
Contemp Oncol (Pozn). 2015;19(1A):A68-77
pubmed: 25691825
Tumour Biol. 2015 May;36(5):3129-36
pubmed: 25809705
J Med Genet. 2015 Oct;52(10):710-8
pubmed: 26358722
J Renin Angiotensin Aldosterone Syst. 2016 Jul-Sep;17(3):1470320316663327
pubmed: 28304186
Am J Transl Res. 2017 May 15;9(5):2327-2339
pubmed: 28559983
Clin Oral Investig. 2018 Jan;22(1):401-409
pubmed: 28616749
Tumour Biol. 2017 Jun;39(6):1010428317701308
pubmed: 28651495
Tumour Biol. 2017 Jul;39(7):1010428317711315
pubmed: 28671039
Sci Rep. 2017 Nov 16;7(1):15683
pubmed: 29146991
Oncotarget. 2017 Nov 30;8(66):110552-110565
pubmed: 29299168
Oncogenesis. 2018 Jan 23;7(1):4
pubmed: 29358619
Clin Chim Acta. 2018 Jun;481:99-107
pubmed: 29501692
Theranostics. 2018 Feb 12;8(7):1850-1868
pubmed: 29556360
Oncol Lett. 2018 May;15(5):6115-6122
pubmed: 29616093
Int J Biol Markers. 2018 Apr 1;:1724600818768459
pubmed: 29690802
Biomed Pharmacother. 2018 Mar;99:638-644
pubmed: 29710461
Cancer. 1993 Oct 15;72(8):2389-93
pubmed: 8402454